Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05611931 · ClinicalTrials.gov registry record · Phase 3
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
A Phase 3 study of Endometrial Cancer, sponsored by Karyopharm Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 276
- Enrollment target
- 20
- Study locations
NCT05611931: Recruiting Phase 3 study of Endometrial Cancer, sponsored by Karyopharm Therapeutics.
NCT05611931 is a Phase 3 study of Endometrial Cancer that is actively recruiting participants, run by Karyopharm Therapeutics. The registered enrollment target is 276 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05611931, a Phase 3 study of Endometrial Cancer, is actively recruiting participants, sponsored by Karyopharm Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 276 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Matching Placebo for selinexor
Study Locations (20)
California
- UC DAVIS - Davis
- City of Hope National Medical Center - Duarte
- Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- City of Hope at Irvine Lennar - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
- UCLA - Women's Health Clinical Research Unit - Los Angeles
- Long Beach Memorial Medical Center - Los Angeles
- UC Irvine - Orange
- Stanford University - Palo Alto
- California Pacific Medical Center - San Francisco
Florida
- Broward Health Medical Center - Fort Lauderdale
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Advent Health - Orlando
Colorado
- Highlands Ranch Hospital - Highlands Ranch
- University of Colorado Cancer Center - Highlands Ranch
Georgia
- Grady Hospital - Atlanta
- Emory University - Atlanta
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- Honor Health - Phoenix
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2028-01 |
| Phase | Phase 3 |
What NCT05611931 shows while recruiting
NCT05611931 is an interventional study that assigns participants to a tested intervention. The registered 276 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Selinexor is the first listed.
NCT05611931 names 20 study sites across 7 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT05611931 about?
NCT05611931 is a clinical study titled "Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma". The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1....
What is the current status of trial NCT05611931?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 276 participants. The study started on 2023-04-18. Estimated completion is 2028-01.
What conditions does trial NCT05611931 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT05611931?
The interventions under investigation include: Selinexor (DRUG), Matching Placebo for selinexor (DRUG).
Who is sponsoring clinical trial NCT05611931?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05611931 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05611931's enrollment target sits among peer trials
276 48th of 181 higher than 134 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RECRUITING · Phase 3
-
Vaginal Cuff Brachytherapy Fractionation Study
RECRUITING · Phase 3
-
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RECRUITING · Phase 3
-
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RECRUITING · Phase 3
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01371630 · 276 participants · Phase 1
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
- NCT04192344 · 276 participants · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
- NCT05294991 · 276 participants · NA
Wellness App for Sleep Disturbance in Hematological Cancer Patients
- NCT05610852 · 276 participants · NA
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI